Barclays upgrades Givaudan stock rating and target to CHF 3,850

Published on 10/05/2026 at 14:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wellbeing growth slowed to 1.50 percent in the second quarter. Givaudan stock costs EUR 3,641.00 on October 5, 2026 versus EUR 3,621.50.

An extreme macro photograph of deep red rose petals. The petal surface is covered in dozens of glistening transparent essential oil droplets catching warm side light. The background dissolves into a soft red and orange bokeh. Fine surface textures, veins, — Givaudan CH0010645932 Makro-Aufnahme roter Rosenblätter mit glitzernden ätherischen Duftöl-Tropfen in warmem Licht, Illustration mit AI erstellt.

Givaudan (ISIN CH0010645932) was trading at EUR 3,641.00 at Lang & Schwarz on October 5, 2026 at 2:30 p.m. CEST, plus 0.54 percent versus the prior close of EUR 3,621.50. According to Investing.com on October 5, 2026, Barclays upgraded the stock from Equalweight to Overweight and raised its price target from CHF 3,450.00 to CHF 3,850.00.

Barclays sees operational resilience

The target change gives the latest analyst view a clear numerical anchor. Barclays said Givaudan has proved more resilient than expected, while management continues to guide to flat margins in 2026 despite higher oil prices.

Investing.com reported on October 5, 2026 that Barclays expects group organic sales growth of 5.60 percent in the third quarter and 6.10 percent in the fourth quarter. The bank also raised its 2027 adjusted EBITDA forecast to CHF 2.02 billion and expects 2027 adjusted earnings per share of CHF 142.03, versus consensus of CHF 130.21.

Taste and Wellbeing remains the test

The counterweight is visible in the second-quarter operating trend. Taste and Wellbeing organic sales growth slowed to 1.50 percent, while weakness in Health and Functional weighed on the division, according to Yahoo Finance on October 5, 2026.

That makes the next report especially relevant for the stock narrative. Givaudan is scheduled to report third-quarter results on October 13, 2026, giving investors a near-term test for the expected recovery in Taste and Wellbeing and Fine Fragrance.

Stock valuation and trading range

Givaudan trades on SIX under ticker GIVN and had a CHF 31.3 billion market capitalization as of October 5, 2026. The finance data quote showed a CHF 2,566.00 to CHF 4,236.00 52-week range, placing the CHF primary-market quote of CHF 3,396.00 inside that span at 2:16 p.m. CEST.

The latest euro quotation was modestly positive rather than a large directional move. At Lang & Schwarz, Givaudan was trading at EUR 3,641.00 on October 5, 2026 at 2:30 p.m. CEST, plus 0.54 percent versus the EUR 3,621.50 prior close of October 2, 2026. The further course of trading is shown by the continuously updated real-time quote of Givaudan stock.